生体吸収性血管スキャフォールドの市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

生体吸収性血管スキャフォールド市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の生体吸収性血管スキャフォールド市場規模は、2024年から2030年までCAGR 8.7%で拡大し、2030年には7億1,509万米ドルに達すると予測されています。

同市場は、心血管疾患の有病率の増加と、効果的で低侵襲な治療の必要性によって大きな成長を遂げています。2024 Heart Disease and Stroke Statistics Update Fact Sheetによると、米国では心臓血管疾患（CVD）は依然として公衆衛生上の重大な問題であり、2021年には931,578人が心臓血管疾患を根本原因として死亡しています。心臓病と脳卒中が2021年にもたらす影響は驚異的で、がんと慢性呼吸器疾患の合計よりも多くの命を奪っています。

CVDの有病率は驚くほど高く、2017年から2020年の間に1億2,790万人の米国成人（48.6%）が何らかの形でCVDに罹患しています。CVDの経済的負担も相当なもので、2019年から2020年の間に、直接的コスト2,543億米ドル、生産性損失と死亡率1,680億米ドルを含む、直接的・間接的コストの合計が4,223億米ドルに上ります。これらの統計は、米国で増大する心血管疾患の負担に対処するための継続的な調査、予防、治療の取り組みが緊急に必要であることを強調しています。

CVDの有病率の増加に加え、生体吸収性血管スキャフォールド（BVS）の技術的進歩や堅調な製品パイプラインも、予測期間中の市場成長を促進すると予想されるその他の要因です。例えば、メーカーであるアボット社の発表によると、2024年4月、米国食品医薬品局は、膝下（BTK）膝窩下疾患患者に対するエベロリムス溶出性生体吸収性足場（Esprit BTK）を承認しました。今回の承認は、BVS市場における継続的な開発と技術革新を浮き彫りにするものであり、心血管系疾患の患者に新たな治療選択肢を提供するものです。

さらに、機械的特性を強化した次世代の生体吸収性血管スキャフォールド（BRS）の進化は、世界市場の拡大を牽引する重要なカタリストとなっています。これまでのBRSは、支柱の太さや交差プロファイルの高さなどの課題に直面し、その普及が制限されていました。しかし、最新のBRSは優れた機械的特性を持つ吸収性材料を利用しているため、より細いストラットの製造と交差プロファイルの低減が可能となり、複雑な病変や細い血管に対する送達性、適合性、柔軟性が向上しています。

このような進歩は、血管の治癒促進、再狭窄率の低下、ステント血栓症などの有害事象のリスク低減などの臨床転帰の改善をもたらし、世界中でBRSの採用が増加しています。低侵襲治療への嗜好の高まり、人口の高齢化、心血管疾患の世界の有病率の上昇は、世界規模での市場の有望な軌道を示しています。

生体吸収性血管スキャフォールド市場レポートハイライト

• 冠動脈セグメントは2023年に84.59%の収益シェアを占めました。これは、冠動脈疾患の有病率の高さと低侵襲治療への需要の高まりによるものです。さらに、生体吸収性足場技術の進歩により、デバイスの性能と患者の転帰が改善され、このセグメントの成長をさらに促進しています。
• 病院セグメントは、2023年に74.21％を超える最大の収益シェアを占めました。これは、病院で行われる心血管処置の量が多く、高度な医療設備が利用できるためです。例えば、米国心臓病学会によると、2023年に米国の病院は90万件以上の冠動脈インターベンションを実施しました。この処置件数の多さは、長期合併症の減少や患者転帰の改善といった生体吸収性血管スキャフォールドの利点と相まって、病院セグメントのトップシェアに貢献しています。
• 2023年には北米が市場シェアをリードしたが、これは心血管疾患を患う患者が多く、ヘルスケアインフラが確立しており、先進医療技術の採用率が高いためです。さらに、この地域には、アボット、ボストン・サイエンティフィック・コーポレーション、メドトロニックなど、革新的な製品を開発し、市場でのプレゼンスを拡大するために研究開発活動に継続的に投資している市場の主要企業が複数存在します。
• 市場参入各社は、さまざまな地域にわたって製品のリーチと可用性を高めるために、さまざまな戦略的イニシアチブを実施しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 生体吸収性血管スキャフォールド市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 生体吸収性血管スキャフォールド市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 生体吸収性血管スキャフォールド市場：用途の推定・動向分析

• 生体吸収性血管スキャフォールド市場：用途ダッシュボード
• 生体吸収性血管スキャフォールド市場：用途変動分析
• 生体吸収性血管スキャフォールド市場の規模と予測および動向分析、用途別、2018～2030年
• 末梢動脈
• 冠状動脈

第5章 世界の生体吸収性血管スキャフォールド市場：最終用途の推定・動向分析

• 生体吸収性血管スキャフォールド市場：最終用途ダッシュボード
• 生体吸収性血管スキャフォールド市場：最終用途変動分析
• 生体吸収性血管スキャフォールド市場の規模と予測および動向分析、最終用途別、2018～2030年
• 病院
• 外来診療センター（ACS）
• 専門クリニック

第6章 生体吸収性血管スキャフォールド市場：国、製品、最終用途別の地域推定・動向分析

• 生体吸収性血管スキャフォールド市場：地域ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 主要メーカーによる最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Abbott
  • Kyoto Medical
  • Biotronik
  • Elixir Medical
  • CR Bard, Inc.,
  • Teleflex Incorporated
  • B. Braun Melsungen AG
  • Medtronic Plc
  • Argon Medical Devices, Inc

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 4 Global bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 5 North America bioresorbable vascular scaffold market, by region, 2018 - 2030 (USD Million)
• Table 6 North America bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 7 North America bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 8 U.S. bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 9 U.S. bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 10 Canada bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 11 Canada bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 13 Mexico bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 14 Europe bioresorbable vascular scaffold market, by country, 2018 - 2030 (USD Million)
• Table 15 Europe bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 16 Europe bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 17 UK bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 18 UK bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany bioresorbable vascular scaffold market, by product type, 2018 - 2030 (USD Million)
• Table 20 Germany bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 21 France bioresorbable vascular scaffold market, by product type, 2018 - 2030 (USD Million)
• Table 22 France bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 23 Italy bioresorbable vascular scaffold market, by product type, 2018 - 2030 (USD Million)
• Table 24 Italy bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Spain bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 26 Spain bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 27 Norway bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 28 Norway bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 29 Sweden bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 30 Sweden bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Denmark bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 32 Denmark bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific bioresorbable vascular scaffold market, by country, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 36 Japan bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 37 Japan bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 38 China bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 39 China bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 40 India bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 41 India bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 42 Australia bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 43 Australia bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 44 South Korea bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 45 South Korea bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 46 Thailand bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 47 Thailand bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 48 Latin America bioresorbable vascular scaffold market, by country, 2018 - 2030 (USD Million)
• Table 49 Latin America bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 50 Latin America bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 51 Brazil bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 52 Brazil bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 53 Argentina bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 54 Argentina bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 55 Middle East & Africa bioresorbable vascular scaffold market, by country, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 58 South Africa bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 59 South Africa bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 62 UAE bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 63 UAE bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)
• Table 64 Kuwait bioresorbable vascular scaffold market, by application, 2018 - 2030 (USD Million)
• Table 65 Kuwait bioresorbable vascular scaffold market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 QFD modelling for market share assessment
• Fig. 6 Market formulation & validation
• Fig. 7 Market outlook
• Fig. 8 Bioresorbable vascular scaffold market segmentation
• Fig. 9 Penetration & growth prospect mapping
• Fig. 10 Market trends & outlook
• Fig. 11 Market driver relevance analysis (Current & future impact)
• Fig. 12 Market restraint relevance analysis (Current & future impact)
• Fig. 13 Bioresorbable vascular scaffold market application market share analysis, 2023 & 2030
• Fig. 14 Bioresorbable vascular scaffold market application market: Application Segment dashboard
• Fig. 15 Peripheral artery market, 2018 - 2030 (USD Million)
• Fig. 16 Coronary artery market, 2018 - 2030 (USD Million)
• Fig. 17 Bioresorbable vascular scaffold market by end-use market share analysis, 2023 & 2030
• Fig. 18 Bioresorbable vascular scaffold market by end-use market: Segment dashboard
• Fig. 19 Hospitals, 2018 - 2030 (USD Million)
• Fig. 20 Ambulatory Care Centers, 2018 - 2030 (USD Million)
• Fig. 21 Speciality Clinics, 2018 - 2030 (USD Million)
• Fig. 22 Bioresorbable vascular scaffold market by regional market share analysis, 2023 & 2030
• Fig. 23 Bioresorbable vascular scaffold market: Regional dashboard
• Fig. 24 Regional marketplace: Key takeaways
• Fig. 25 North America bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 26 U.S. bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 27 Canada bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 28 Mexico bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 29 Europe bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 30 UK bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 31 France bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 32 Germany bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 33 Italy bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 34 Spain bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 35 Denmark bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 36 Norway bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 37 Sweden bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 38 Asia Pacific bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 39 Japan bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 40 China bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 41 India bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 42 Australia bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 43 South Korea bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 44 Thailand bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 45 Latin America bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 46 Brazil bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 47 Argentina bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 48 MEA bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 49 Saudi Arabia bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 50 South Africa bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 51 UAE bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 52 Kuwait bioresorbable vascular scaffold market, 2018 - 2030 (USD Million)
• Fig. 53 Company market position analysis

Bioresorbable Vascular Scaffold Market Growth & Trends:

The global bioresorbable vascular scaffold market size is expected to reach USD 715.09 million by 2030, expanding at a CAGR of 8.7% from 2024 to 2030, based on a new Grand View Research, Inc. report. The market is experiencing significant growth driven by the increasing prevalence of cardiovascular diseases and the need for effective, minimally invasive treatments. According to the 2024 Heart Disease and Stroke Statistics Update Fact Sheet, cardiovascular disease (CVD) remains a significant public health concern in the U.S., with 931,578 deaths attributed to it as the underlying cause in 2021. The impact of heart disease and stroke is staggering, as they claimed more lives in 2021 than all forms of cancer and chronic lower respiratory disease combined.

The prevalence of CVD is alarmingly high, with 127.9 million US adults (48.6%) having some form of the disease between 2017 and 2020. The economic burden of CVD is also substantial, with direct and indirect costs totaling USD 422.3 billion between 2019 and 2020, including USD 254.3 billion in direct costs and USD 168.0 billion in lost productivity and mortality. These statistics underscore the urgent need for continued research, prevention, and treatment efforts to address the growing burden of cardiovascular disease in the U.S.

In addition to the increasing prevalence of CVD, technological advancements in the bioresorbable vascular scaffold (BVS) and a robust product pipeline are other factors expected to drive the growth of the market during the forecast period. For instance, in April 2024, the US Food and Drug Administration approved an everolimus-eluting bioresorbable scaffold (Esprit BTK) for patients with below-the-knee (BTK) infrapopliteal disease, according to an announcement from manufacturer Abbott. This approval highlights the ongoing development and innovation in the BVS market, providing new treatment options for patients with cardiovascular conditions.

Moreover, the evolution of next-generation bioresorbable vascular scaffolds (BRSs) with enhanced mechanical properties is a significant catalyst driving the global market's expansion. Previous versions of BRSs encountered challenges such as thicker struts and higher crossing profiles, limiting their widespread application. However, the latest BRSs utilize absorbable materials with superior mechanical attributes, enabling the production of thinner struts and reduced crossing profiles, improving deliverability, conformability, and flexibility for complex lesions and smaller vessels.

These advancements have resulted in improved clinical outcomes, including enhanced vessel healing, reduced restenosis rates, and decreased risks of adverse events like stent thrombosis, fostering increased adoption of BRSs worldwide. The growing preference for minimally invasive procedures, an aging population, and the escalating prevalence of cardiovascular diseases globally indicate a promising trajectory for the market on a global scale.

Bioresorbable Vascular Scaffold Market Report Highlights:

• The coronary artery segment accounted for a revenue share of 84.59% in 2023. This is due to the high prevalence of coronary artery diseases and the increasing demand for minimally invasive treatments. Additionally, the advancements in bioresorbable scaffold technology have led to improved device performance and patient outcomes, further driving the growth of this segment.
• The hospitals segment held the largest revenue share of over 74.21% in 2023. This is due to the high volume of cardiovascular procedures performed in hospitals and the availability of advanced medical facilities. Additionally, hospitals often serve as referral centers for complex cases, further driving the demand for bioresorbable vascular scaffolds.For instance, in 2023, hospitals in the U.S. performed over 900,000 coronary interventions, according to the American College of Cardiology. This high procedure volume, coupled with the benefits of bioresorbable vascular scaffolds, such as reduced long-term complications and improved patient outcomes, contributes to the hospital segment's leading market share.
• In 2023, North America led the market share, due to the presence of a large patient pool suffering from cardiovascular diseases, a well-established healthcare infrastructure, and a high adoption rate of advanced medical technologies. Additionally, the region is home to several key players in the market, such as Abbott, Boston Scientific Corporation, and Medtronic, which are continuously investing in R&D activities to develop innovative products and expand their market presence.
• Market players are implementing various strategic initiatives to enhance product reach and availability across different geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application Type
  • 1.2.2. End-use channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Segment
  • 2.2.2. End-use Segment
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Bioresorbable Vascular Scaffold Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Bioresorbable Vascular Scaffold Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Bioresorbable Vascular Scaffold Market: Application Estimates & Trend Analysis

• 4.1. Bioresorbable Vascular Scaffold Market: Application Dashboard
• 4.2. Bioresorbable Vascular Scaffold Market: Application Movement Analysis
• 4.3. Bioresorbable Vascular Scaffold Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Peripheral Artery
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Coronary Artery
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Global Bioresorbable Vascular Scaffold Market: End-use Estimates & Trend Analysis

• 5.1. Bioresorbable Vascular Scaffold Market: End-use Dashboard
• 5.2. Bioresorbable Vascular Scaffold Market: End-use Movement Analysis
• 5.3. Bioresorbable Vascular Scaffold Market Size & Forecasts and Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Ambulatory Care Centers (ACS)
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Specialty Clinics
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Bioresorbable Vascular Scaffold Market: Regional Estimates & Trend Analysis by Country, Product, and End-use

• 6.1. Bioresorbable Vascular Scaffold Market: Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Regulatory framework/ reimbursement structure
    • 6.3.4.3. Competitive scenario
    • 6.3.4.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.9. Denmark
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Regulatory framework/ reimbursement structure
    • 6.4.9.3. Competitive scenario
    • 6.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.3. South Africa
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Abbott
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Application benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Kyoto Medical
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Application benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Biotronik
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Application benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Elixir Medical
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Application benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. C. R. Bard, Inc.,
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Application benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Teleflex Incorporated
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Application benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. B. Braun Melsungen AG
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Application benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Medtronic Plc
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Application benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Argon Medical Devices, Inc
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Application benchmarking
    • 7.3.12.4. Strategic initiatives